Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EASi-HF Preserved
jRCT2051240109Phase 3Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2024
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in heart failure with preserved ejection fraction (HFpEF) and heart failure with mid-range ejection fraction (HFmrEF) comparing Vicadrostat + empagliflozin with Placebo + empagliflozin (2 arms). Primary endpoint: Time to first event of cardiovascular death or hospitalization for heart failure. Started Sep 2024; status: recruiting.
02
Drugs
vicadrostatempagliflozin
03
Conditions
heart failure with preserved ejection fraction (HFpEF)heart failure with mid-range ejection fraction (HFmrEF)
Beyond the preview
Go deeper on jRCT2051240109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240109.